# Clinical Trial Submission Process

March 25, 2021

Brandi Weaver, BA – Manager, Clinical Trials Development Patricia Miranda, BBA – Manager, Research Operations



# Reminder during the Forum:

## The session will be recorded

- Mute your mics to avoid echoing or background noise
- Do not activate your camera to preserve bandwidth
- In lieu of voicing your questions, use the chat function, a moderator will respond to your question



# VPR CTO Overview





# **Clinical Trial Portal Submissions**

Clinical trials must be reviewed and cleared by the Clinical Trials Office (CTO) before the research application can be submitted to the Institutional Review Board (IRB).

- Be prepared to upload the following files to the portal:

If **externally sponsored trial**, the sponsor's protocol

If **industry sponsored trial**, the sponsor's protocol, Clinical Trial Agreement/Study Agreement and Proposed site budget



# **Clinical Trial Portal Submissions**

#### If **investigator-initiated trial**, the <u>Clinical</u> <u>Trial Protocol Template (Form CT)</u> or stand-alone Investigator initiated study (IIS) protocol

If not provided in the protocol, include a list of all study procedures, frequency and timing using the

#### **Schedule of Events Template**

## **Clinical Trial Portal**



#### Submission Form

#### Welcome!

Use this online form to initiate contact and the start up process for a new clinical trial at UT Health San Antonio or to submit a "cancer related" non-clinical trial.

#### Who should use this portal?

- · UTHealthSA Investigators planning a new clinical trial or cancer related research
- Industry Sponsors, CRO's, Cooperative Groups and Networks interested in placing a new trial at UTHealthSA.

#### What happens next?

One of our two Clinical Trials Offices will assist you with the study startup process.

- The Mays Cancer Center CTO coordinates all cancer related trials.
- The VPR CTO coordinates all other (non-cancer) trials.



#### **Applicable Clinical Trials**

#### **Clinical Trial Determination**





# **Clinical Trial Modifications**



During CTO review for a new study

### When do I submit study changes to the Clinical Trials Office (CTO)?



After CTO Clearance but before submission to OCR/IRB for a new study



## New Studies under CTO Review or cleared by CTO but not yet submitted to OCR/IRB

Research Team to submit modification/amendment to Clinical Trials Office (CTO) via VPRCTO@uthscsa.edu for secondary review and re-clearance.

This will include:

- Submitting CTO pertinent documents to <u>VPRCTO@uthscsa.edu</u>. For example, modifications to the CTO coverage analysis (CA), protocol, budget or study manuals/documents that may affect budget or study operations.
  - CTO will review for any changes to study title, study sites, study design or procedures, personnel or finances, and work with the research team to update coverage analysis and/or budget
- CTO will route final revised forms to Service Providers and Affiliates for secondary review and clearance (UHS, FORU, Radiology etc.), if applicable
  - Updated service provider agreements and pricing will be obtained, if applicable
- CTO will route revised budget or finance forms to OSP for review
  - Amended CTA and/or study agreement will be executed, if applicable



# **Clinical Trial Modifications**

When do I submit study changes to the IRB/OCR?



IRB/OCR amendment after the study is OCR/IRB approved



# New Studies submitted to OCR/IRB

(after CTO clearance and approval)

- When your new study has already been submitted to OCR/IRB or has received IRB and/or Institutional approval.
- If your new study has been approved, changes should be incorporated on the IRB/OCR approved "CA.doc" as part of an IRB/OCR amendment or modification
- OCR/IRB will trigger CTO review once amendment or modification is received, if applicable
- CTO will reach out to research team to update any applicable CTO documents (CA, budget, CTA etc.)





## **CTO Amendment Process**





# **CTO Coverage Analysis (CA)**

## **CTO Excel CA**

Study Specific Informatio

CTMS Number: 21-00xx	Regulatory Sponsor: Pharmaceutical Sponsor	
IRB Number:	Pfizer Funding Sponsor:	
HSC20210xxxH	(For Profit)	
rincipal Investigator: Dr. John Doe	Protocol Number: WHO1234	
	NCT Number: NCT0001234	
	IND/IDE Number: N/A	
A Version and Date: CA V1.0, 2021-03-18	Enrollment Target: Local enrollment goal	

## Regulatory CA (CA.doc Word document)

CTMS Number: 21-00xx	Regulatory Sponsor:	Sponsor
IRB Number:	Funding Sponsor:	Pfizer
HSC20210xxxH		(For Profit)
Principal Investigator: Dr. John Doe	Protocol Number:	WH01234
	NCT Number:	NCT0001234
	IND/IDE Number:	N/A
CA Version and Date: CA V1.0, 2021-03-1	Enrollment Target:	Local enrollment goal

#### **Detailed Study Coverage Analysis**

Event/Procedure Name	Is this a Routine Procedure?	Site or Location Service is Provided	Who is completing the Event/Procedure?	Comments on Location/Coverage Determination	Total Quantity
Informed Consent	Research Only	UT - UT Health San Antonio	UT - Clinical/Research Staff		1.0
				1	0.0
1		H	-	1	0.0



Event/Procedure Name - CC			Is this a Who is Paying Routine for this	this Site or Location Service is	Who is completing the • Event/Procedure? •	Comments on Location/Coverage Determination	✓ Total Quantif -	Visit 01 Baseline
		Routine for t						
	- CODE/CF -		Service?					
Informed Consent	1111	Research Only	R - Research Paid	UT - UT Health San Antonio	UT - Clinical/Research Staff		2.00	1.00
				1	1		0.00	
				1			0.00	
							0,00	
							0.00	

#### Amendment Notification during Mid-Budget Negotiation



#### Timely Communication is key

- Direction from the PI and research team will be required to determine the best course of action
- CTO Budget Analyst will recommend either continuing with the current version on file if budget negotiation with the sponsor has commenced

### OR

• Take immediate action to review the amendment and incorporate changes



### CTO assistance during close-out steps

## Task Teams Close-Out Steps

- Billing Risk
  - EPIC Research Account Inactivation
- Participant Payments
  - ClinCard Study Closure
  - Bursar Office Notification
- Velos eResearch Study Inactivation
- Triggers Close-Out Invoices
  - (if CTO negotiated the budget)





# Questions?

### **Clinical Trials Office Staff**

- Jason Bates, MBA Director, CTO
- Patricia Miranda, BBA Manager, Research Operations
- Brandi Weaver, BA Manager, Clinical Trials Development
- Cathy Haegelin, BBA, MBA, CPA Budget Analyst Senior
- Lynda Schrack, BA Clinical Trials Specialist
- Cristina Morales, BSBA Clinical Trials Specialist
- Anna Stewart, Budget Analyst Intermediate
- Christie Bryant, BBA Billing Analyst



## Upcoming Forum & Concierge Dates:

#### **Research Concierge Dates:**

\*VPR Virtual TEAMs Meeting Scheduler (link below)\*

- Tuesday, April 6, 2021, 1pm 4pm
- Wednesday, April 7, 2021, 9am 12pm
- Wednesday, April 21, 2021 9am 12pm

**Research Concierge Virtual Scheduler** 

Next Forum Date:

- Thursday, April 22, 2021, 1pm 2pm
- via Zoom



